RGT Stock Overview
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.43 |
| 52 Week High | AU$9.00 |
| 52 Week Low | AU$0.30 |
| Beta | 0.98 |
| 1 Month Change | 0% |
| 3 Month Change | 7.50% |
| 1 Year Change | -94.63% |
| 3 Year Change | -99.30% |
| 5 Year Change | -99.14% |
| Change since IPO | -99.70% |
Recent News & Updates
Recent updates
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Jun 23
MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?
Mar 09Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)
Oct 08If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns
Feb 21
What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?
Dec 30Shareholder Returns
| RGT | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -3.4% | -3.0% | -2.2% |
| 1Y | -94.6% | 37.1% | 4.5% |
Return vs Industry: RGT underperformed the Australian Pharmaceuticals industry which returned 37.1% over the past year.
Return vs Market: RGT underperformed the Australian Market which returned 4.5% over the past year.
Price Volatility
| RGT volatility | |
|---|---|
| RGT Average Weekly Movement | 14.4% |
| Pharmaceuticals Industry Average Movement | 11.1% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: RGT's share price has been volatile over the past 3 months.
Volatility Over Time: RGT's weekly volatility has decreased from 39% to 14% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Roby Zomer | mgcpharma.com.au |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
| RGT fundamental statistics | |
|---|---|
| Market cap | AU$18.56m |
| Earnings (TTM) | -AU$17.02m |
| Revenue (TTM) | AU$1.32m |
14.7x
P/S Ratio-1.1x
P/E RatioIs RGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RGT income statement (TTM) | |
|---|---|
| Revenue | AU$1.32m |
| Cost of Revenue | AU$1.20m |
| Gross Profit | AU$125.39k |
| Other Expenses | AU$17.14m |
| Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 9.47% |
| Net Profit Margin | -1,284.89% |
| Debt/Equity Ratio | 1,366.5% |
How did RGT perform over the long term?
See historical performance and comparison